Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines.
D'Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, Degan M, Zaja F, Bulian P, Bo MD, Ferrero S, Ladetto M, Zamò A, Gattei V, Bomben R. D'Agaro T, et al. Among authors: zaja f. Haematologica. 2019 Sep;104(9):e410-e414. doi: 10.3324/haematol.2018.212811. Epub 2019 Feb 28. Haematologica. 2019. PMID: 30819916 Free PMC article. No abstract available.
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.
Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, Rossi FM, Monti S, Degan M, Ciardullo C, Serra R, Zucchetto A, Nomdedeu J, Bulian P, Grossi A, Zaja F, Pozzato G, Laurenti L, Efremov DG, Di-Raimondo F, Marasca R, Forconi F, Del Poeta G, Gaidano G, Gattei V. Rossi D, et al. Among authors: zaja f. Blood. 2013 Jun 13;121(24):4902-5. doi: 10.1182/blood-2013-02-486209. Epub 2013 May 1. Blood. 2013. PMID: 23637131 Free article. Clinical Trial.
CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism.
Zucchetto A, Caldana C, Benedetti D, Tissino E, Rossi FM, Hutterer E, Pozzo F, Bomben R, Dal Bo M, D'Arena G, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Rossi D, Gaidano G, Del Poeta G, Gattei V. Zucchetto A, et al. Among authors: zaja f. Blood. 2013 Nov 7;122(19):3317-21. doi: 10.1182/blood-2013-06-507335. Epub 2013 Sep 25. Blood. 2013. PMID: 24068493 Free article.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Among authors: zaja f. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F, Dal Bo M, Peragine N, Bomben R, Zucchetto A, Rossi F, Degan M, Rossi D, Chiarenza A, Grossi A, Di Raimondo F, Zaja F, Pozzato G, Secchiero P, Gaidano G, Del Poeta G, Zauli G, Fo À R, Guarini A, Gattei V. Pozzo F, et al. Among authors: zaja f. J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83. J Hematol Oncol. 2013. PMID: 24283248 Free PMC article.
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.
Dal Bo M, D'Agaro T, Gobessi S, Zucchetto A, Dereani S, Rossi D, Zaja F, Pozzato G, Di Raimondo F, Gaidano G, Laurenti L, Del Poeta G, Efremov DG, Gattei V, Bomben R. Dal Bo M, et al. Among authors: zaja f. Oncotarget. 2015 Aug 7;6(22):19102-17. doi: 10.18632/oncotarget.3905. Oncotarget. 2015. PMID: 26036258 Free PMC article.
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation.
Pozzo F, Bittolo T, Arruga F, Bulian P, Macor P, Tissino E, Gizdic B, Rossi FM, Bomben R, Zucchetto A, Benedetti D, Degan M, D'Arena G, Chiarenza A, Zaja F, Pozzato G, Rossi D, Gaidano G, Del Poeta G, Deaglio S, Gattei V, Dal Bo M. Pozzo F, et al. Among authors: zaja f. Leukemia. 2016 Jan;30(1):182-9. doi: 10.1038/leu.2015.182. Epub 2015 Jul 13. Leukemia. 2016. PMID: 26165233 Free article.
Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
Benedetti D, Tissino E, Caldana C, Dal Bo M, Bomben R, Marconi D, Ganghammer S, Zaja F, Pozzato G, Di Raimondo F, Hartmann TN, Del Poeta G, VanMeter A, Zucchetto A, Espina V, Liotta L, Gattei V. Benedetti D, et al. Among authors: zaja f. Leukemia. 2016 Feb;30(2):513-7. doi: 10.1038/leu.2015.149. Epub 2015 Jun 19. Leukemia. 2016. PMID: 26183532 No abstract available.
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.
Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A, Bulian P, Visco C, Mauro FR, Morabito F, Cortelezzi A, Zaja F, Forconi F, Laurenti L, Del Giudice I, Gentile M, Vincelli I, Motta M, Coscia M, Rigolin GM, Tedeschi A, Neri A, Marasca R, Perbellini O, Moreno C, Del Poeta G, Massaia M, Zinzani PL, Montillo M, Cuneo A, Gattei V, Foà R, Gaidano G. Rossi D, et al. Among authors: zaja f. Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14. Blood. 2015. PMID: 26276669 Free PMC article. Clinical Trial.
242 results